SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by O'Toole, D
Right arrow Articles by Love, W C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Toole, D
Right arrow Articles by Love, W C
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Interferon-ß-1b and interferon-{gamma} have similar inhibitory effects on apolipoprotein-E production in the monocyte/macrophage

D O'Toole

Department of Biochemistry, Trinity College, University of Dublin, Dublin 2, Ireland, dotoole{at}tcd.ie

W C Love

Department of Biochemistry, Trinity College, University of Dublin, Dublin 2, Ireland

Apolipoprotein-E (Apo-E) is the major lipid carrier in the brain, and is therefore important in the recycling of lipids and cholesterol to regenerating neurons during the remission phase of multiple sclerosis (MS). Interferon (IFN)-{gamma} has been shown to inhibit Apo-E production by a mainly post-transcriptional method in a macrophage cell line, and reduced Apo-E in cerebrospinal fluid is noted during the remission phase in patients. IFN-ß-1b is a recombinantly produced, anti-inflammatory cytokine, which has been shown to reduce the severity of MS relapses and reduce relapse rate. We have examined the effects of IFN-{gamma} and IFN-ß-1b on the production of Apo-E mRNA, cellular protein and secreted protein in primary monocytes derived from donor blood. IFN-ß-1b does not relieve the dose-dependent inhibition of Apo-E seen with IFN-{gamma} at up to 100 U/ml in these cells, and when used alone inhibits Apo-E production in a dose-dependent manner. This inhibition by IFN- ß-1b was seen to be at a transcriptional level, and dose dependent up to 100 U/ml. Apo-E genotype, which has also been linked to failure to recover from MS relapses, did not affect this inhibition. The mode of action of IFN-ß-1b in MS is therefore not thought to be through modification of Apo-E production.

Key Words: apolipoprotein-E • interferon beta • interferon gamma • monocytes • multiple sclerosis

Multiple Sclerosis, Vol. 8, No. 2, 124-129 (2002)
DOI: 10.1191/1352458502ms784oa


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement